Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Bethel

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Antimicrobial Agents and Chemotherapy|September 25, 2004
Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamasesAndrea M Hujer, Christopher R Bethel, Robert A Bonomo
Antimicrobial Agents and Chemotherapy|January 16, 2007
Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamasesJodi M Thomson, Fabio Prati, Christopher R Bethel, et al.
Biochemistry|November 3, 2004
Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variantTao Sun, Christopher R Bethel, Robert A Bonomo, et al.
Biochemistry|September 10, 2009
Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitorsMatthew Kalp, Christopher R Bethel, Robert A Bonomo, et al.
FEMS Microbiology Letters|April 28, 2004
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibitionChristopher R Bethel, Andrea M Hujer, Marion S Helfand, et al.
Clinics in Laboratory Medicine|June 5, 2004
Antibiotic resistance in the institutionalized elderlyAndrea M Hujer, Christopher R Bethel, Kristine M Hujer, et al.
The Journal of Biological Chemistry|January 21, 2014
The different inhibition mechanisms of OXA-1 and OXA-24 β-lactamases are determined by the stability of active site carboxylated lysineTao Che, Christopher R Bethel, Marianne Pusztai-Carey, et al.
Biochemistry|April 20, 2007
Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamasesWei Ke, Christopher R Bethel, Jodi M Thomson, et al.
The Journal of Biological Chemistry|June 15, 2007
Efficient inhibition of class A and class D beta-lactamases by Michaelis complexesMatthew Kalp, Anjaneyulu Sheri, John D Buynak, et al.
Elife|January 21, 2026
Ω-Loop mutations control dynamics of the active site by modulating the hydrogen-bonding network in PDC-3 β-lactamaseShuang Chen, Andrew R Mack, Andrea M Hujer, et al.
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Antimicrobial Agents and Chemotherapy|September 25, 2004
Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamasesAndrea M Hujer, Christopher R Bethel, Robert A Bonomo
Antimicrobial Agents and Chemotherapy|January 16, 2007
Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamasesJodi M Thomson, Fabio Prati, Christopher R Bethel, et al.
Biochemistry|November 3, 2004
Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variantTao Sun, Christopher R Bethel, Robert A Bonomo, et al.
Biochemistry|September 10, 2009
Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitorsMatthew Kalp, Christopher R Bethel, Robert A Bonomo, et al.
FEMS Microbiology Letters|April 28, 2004
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibitionChristopher R Bethel, Andrea M Hujer, Marion S Helfand, et al.
Clinics in Laboratory Medicine|June 5, 2004
Antibiotic resistance in the institutionalized elderlyAndrea M Hujer, Christopher R Bethel, Kristine M Hujer, et al.
The Journal of Biological Chemistry|January 21, 2014
The different inhibition mechanisms of OXA-1 and OXA-24 β-lactamases are determined by the stability of active site carboxylated lysineTao Che, Christopher R Bethel, Marianne Pusztai-Carey, et al.
Biochemistry|April 20, 2007
Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamasesWei Ke, Christopher R Bethel, Jodi M Thomson, et al.
The Journal of Biological Chemistry|June 15, 2007
Efficient inhibition of class A and class D beta-lactamases by Michaelis complexesMatthew Kalp, Anjaneyulu Sheri, John D Buynak, et al.
Elife|January 21, 2026
Ω-Loop mutations control dynamics of the active site by modulating the hydrogen-bonding network in PDC-3 β-lactamaseShuang Chen, Andrew R Mack, Andrea M Hujer, et al.
Pageof 12